Epigral Limited has announced a strategic expansion with its Board approving two new projects: an Epoxy Resin & Formulations plant with a capacity of 125,000 tons per annum and a multipurpose plant. These initiatives aim to strengthen the company’s integrated manufacturing complex, cater to growing domestic demand in various sectors, and enhance its product portfolio. The projects are progressing as per timelines, with pilot facilities expected to be operational by Q2 FY27.
Strategic Expansion into Epoxy Resin and Multipurpose Production
Epigral Limited is set to significantly bolster its manufacturing capabilities with the approval of two key projects by its Board of Directors. These initiatives include the establishment of an Epoxy Resin & Formulations plant with a substantial capacity of 125,000 tons per annum and a versatile multipurpose plant. This strategic expansion is designed to meet the burgeoning demand for high-quality materials driven by India’s growth in infrastructure development, automotive, renewable energy, and electronics sectors.
Integrated Manufacturing and Diversification
The Epoxy Resin & Formulations project leverages Epigral’s existing backward integration, with key raw materials like epichlorohydrin and caustic soda already produced in-house. Over 50% of the raw material value for this project will be sourced internally, thereby strengthening integration advantages and operational efficiency. The multipurpose plant will focus on manufacturing downstream products of the epichlorohydrin and chlorotoluenes value chain, addressing the domestic demand for pharmaceutical and agrochemical intermediates and water treatment chemicals.
Pilot Facilities and Phased Rollout
In line with a phased development approach, Epigral is establishing pilot facilities for both epoxy resin and formulations, and the multipurpose plant. These pilot units are anticipated to be operational by Q2 FY27. Their primary purpose is to validate product quality, optimize manufacturing processes, and secure early customer approvals ahead of full commercial-scale operations. This strategic move forward into Advanced Materials and Specialty Chemicals signifies Epigral’s commitment to building a robust integrated manufacturing platform and diversifying its portfolio for long-term stakeholder value.
Financial Performance Highlights (Q1 FY27)
For the first quarter of FY27, Epigral reported a year-on-year revenue increase of 15% to INR709 crore, driven by improved sales volume and realization. EBITDA grew by 10% to INR179 crore, with an EBITDA margin of 25%. Profit After Tax (PAT) saw a 25% jump to INR99 crore compared to the adjusted PAT of INR79 crore in Q1 FY26. The company also noted a net debt-to-EBITDA of 0.8x and a capital expenditure of INR62 crore in Q1 FY27.
Source: BSE
